AstraZeneca PLC Fourth quarter and full year results 2012

Pascal Soriot, Chief Executive Officer, commenting on the results, said:

"Our performance in 2012 reflects a period of significant patent expiry and tough market conditions globally. Despite the challenges we face, I am excited about AstraZeneca’s fundamental strengths which will be key in returning the Company to growth and achieving scientific leadership while maintaining our reputation for strong financial discipline. It is my firm belief that we have the brands, science, pipeline and people to create distinctive, long-term value for patients and shareholders. Our new leadership team and I look forward to elaborating on these themes at our Capital Markets Day in March."

Fourth quarter and full year results 2012

Announced on Thursday 31 January 2013

• Cautionary statement regarding forward looking statements (PDF 59kb)
• Press release (PDF 352kb)
• Pipeline table (PDF 382kb)

Downloads

• Download presentation (PDF 448kb)
• Pascal Soriot opening script (PDF 106kb)
• Briggs Morrison script (PDF 149kb)
• Simon Lowth script (PDF 109kb)
• Pascal Soriot closing script (PDF 58kb)

Webcast

Contact information

Media Enquiries

Esra Erkal-Paler (London) +44 20 7604 8030
Vanessa Rhodes (London) +44 20 7604 8037
Tony Jewell (Wilmington) +1 302 885 4594
Ann-Leena Mikiver (Södertälje) +46 8 553 260 20/+46 707 428836

Investor Enquiries

James Ward-Lilley (London) +44 20 7604 8122
Karl Hård (London) +44 20 7604 8123
Nicklas Westerholm (London) +44 20 7604 8124
Ed Seage (US) +1 302 886 4065
Colleen Proctor (US) +1 302 886 1842